Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC

June 2011 | 2 pages | ID: T2E1570841AEN
MP Advisors

Abstracts

Roche today announced results from the European EURTAC trial on Tarceva in EGFR+ve first line NSCLC patients. Tarceva improved Progression Free Survival (PFS) by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS benefit, despite showing good PFS benefit in the same population. Iressa is already approved in Europe in Jun 2009 for the treatment of all lines of EGFR positive advanced NSCLC.

Contents

COMPANIES MENTIONED

Roche, AstraZenica, Astellas, ROG, AZN, 4503